[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypoglycemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypoglycemia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,40,76,107,135,158,185,230,257,285,314,341,363,388,415,437,465,487,509,535,561],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":4,"leadSponsor":36,"locationsCount":39},"100054339","diagnosing-and-treating-low-blood-sugar-levels-100054339",false,"NCT00001276","Diagnosing and Treating Low Blood Sugar Levels","Fasting Hypoglycemia: Diagnosis and Treatment","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Male, females ages \\>= 18.\n2. Patients with documented fasting blood glucose below 55 mg\u002Fdl.\n\n4\\. Patients with biochemical evidence for insulinoma or other pancreatic neuroendocrine tumors.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Patients with significant cardiac disease will be excluded.\n2. Subjects who are pregnant per self-report.\n3. Medically unstable per the assessment of the PI.","ALL","18 Years","120 Years",{"count":20,"type":21},1500,"ESTIMATED","OBSERVATIONAL","Hypoglycemia is the term used to refer to lower than normal levels of blood sugar. This study will continue to research the causes of hypoglycemia.\n\nPatients involved in the study will be admitted to the Clinical Center of the National Institutes of Health and undergo tests for evaluating blood sugar. Patients will be required to refrain from eating for a set period of time and will undergo blood tests for insulin levels and several other specific diagnostic tests related to insulin secretion. The patients will be under supervision and will be provided with appropriate medical and surgical attention as needed.",[25,26],"Hypoglycemia","Insulinoma",[25,26,28],"Natural History","RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":33},"1991-05-21",{"name":37,"class":38},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":39},"100538987","impact-of-menstruation-on-glycemic-response-and-exercise-in-females-with-type-1-diabetes-100538987","NCT06297980","Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes","MERIT","Inclusion Criteria:\n\n* Women 18-45 who have had type 1 diabetes for at least 12 months\n* Premenopausal with either menstrual cycles or currently using oral contraceptives\n\nExclusion Criteria:\n\n* Women who are postmenopausal, pregnant, trying to become pregnant, or have had a hysterectomy","FEMALE","45 Years",{"count":50,"type":21},150,"INTERVENTIONAL",[53],"NA","The objectives of this study are to examine how sex hormones (use of hormonal birth control, menstrual cycle phase) impact glycemic control among women with type 1 diabetes (T1D), and to test adjustments to insulin dosing and food intake to ameliorate cycle-related glycemic variability. A secondary aim is to examine how the menstrual cycle and use of hormonal birth control impact patient-reported outcomes and glycemic responses to physical activity.",[56,25,57,58],"Type 1 Diabetes","Hyperglycaemia Due to Type 1 Diabetes Mellitus","Menstruation Disturbances",[60,61,62,63,64,65],"type 1 diabetes","menstrual cycle","exercise","hypoglycemia","hyperglycemia","glucose control","2026-06-15",{"date":68,"type":33},"2026-06-16",{"date":70,"type":33},"2024-03-24",{"date":72,"type":21},"2027-10-31",{"name":74,"class":75},"University of Colorado, Denver","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":51,"phases":85,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100473662","diabetes-clinical-decision-support-100473662","NCT05447806","Diabetes Clinical Decision Support","Glucose Management Clinical Decision Support to Improve Outcomes in Academic and Community Hospitals","Inclusion Criteria:\n\n* Hospitalized adult (\\>18 years) patients at Penn State Health, Hershey Medical Center, St. Joseph's Hospital, Hampden Medical Center, Holy Spirit Medical Center, and Lancaster Medical Center\n* Ambulatory adult (\\>18 years) patients at Penn State Health, Hershey Medical Center, St. Joseph's Hospital, Hampden Medical Center, Holy Spirit Medical Center, and Lancaster Medical Center\n* Trigger of an alert or a disease management message\n\nExclusion Criteria:\n\n* Children (\\\u003C18 years)",{"count":84,"type":21},15732,[53],"The purpose of this study is to determine the impact of an electronic medical record clinical decision support tool on rates of dysglycemia in the hospital, and its clinical and economical outcomes. The study also evaluates the perspectives of providers regarding the tool's usefulness on disease management support, knowledge, and practice performance.",[88,89,90,91,25],"Hyperglycemia","Hyperglycemia Stress","Diabetes","PreDiabetes",[93,94,95,96],"Clinical Decision Support","Electronic Medical Records","Health Systems Science","Hospital Management","2026-05-12",{"date":99,"type":33},"2026-05-14",{"date":101,"type":33},"2022-07-15",{"date":103,"type":21},"2026-10-16",{"name":105,"class":75},"Milton S. Hershey Medical Center",2,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":51,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":39},"100584744","monitoring-exhaled-breath-to-noninvasively-detect-glycemic-events-100584744","NCT06893341","Monitoring Exhaled Breath to Noninvasively Detect Glycemic Events","Monitoring Volatile Organic Compound Profiles in Exhaled Breath to Noninvasively Detect Glycemic Events in Patients With Diabetes","Inclusion Criteria:\n\n* Who are diagnosed with type 1 diabetes.\n* Who are between 12-19 years of age.\n* That utilize a Dexcom (G6 or G7) continuous glucose monitoring device.\n* That have an established working CGM for at least 12 hours (that does not need to be replaced within 24 hours).\n* That are willing to share their daily CGM data for the study.\n* That are the only individuals in their household with any type of diabetes diagnosis (type 1 or type 2).\n* That are willing to return the device within 24-48 hours of study completion.\n* That are located in Indianapolis, IN or its suburban areas.\n\nExclusion Criteria:\n\n* That are smokers or use tobacco products or who live with someone who smokes in their vicinity.\n* That have a condition or abnormality other than type 1 diabetes that in the opinion of the Investigator would compromise the safety of the subject or the quality of the data.\n* That utilize closed-loop diabetes management systems.\n* That have symptoms or recently been diagnosed with an upper respiratory illness including COVID-19.\n* That themselves or a close family member (living within the same household at the time of the data collection period) is on a \"ketogenic diet\".\n* That themselves or a close family member is working in an industry with high and continuous exposure to exogenous VOCs. Examples of such industries include beauty salons and paint manufacturers.\n* That are unable or unwilling to cooperate with sample collection.","12 Years","19 Years",{"count":117,"type":21},30,[53],"The purpose of this study is to determine whether an array of biosensors can noninvasively identify hyperglycemic or hypoglycemic events in persons diagnosed with diabetes through noninvasive detection of volatile organic compounds in exhaled breath.",[90,88,25],[122,123,124,125],"Volatile Organic Compound (VOC)","Electronic Nose (e-Nose)","Exhaled Breath","Noninvasive Health Monitoring","2026-05-08",{"date":128,"type":33},"2026-05-13",{"date":130,"type":33},"2025-10-23",{"date":132,"type":21},"2026-12-01",{"name":134,"class":75},"Indiana University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":39},"100510955","a-study-of-glycemic-control-in-left-ventricular-assist-100510955","NCT05933161","A Study of Glycemic Control in Left Ventricular Assist","GLYcemic Control Evaluation by Continuous Glucose Monitor Compared With a1C in Left Ventricular Assist Device-supported Patients (GLYCEM1C-LVAD)","GLYCEM1C-LVAD","Inclusion Criteria:\n\n* Prior implantation of contemporary, centrifugal flow LVAD (HeartWare or HeartMate 3) at any time after 2010\n* Diagnosis of type II diabetes mellitus\n* Any antihyperglycemic regimen\n* Greater than 3 months out from LVAD implantation\n* Capable of utilizing smartphone device for LibreLink app for uploading glycemic data\n* Patients may be enrolled who have preexisting CGM in place.\n\nExclusion Criteria:\n\n* Type I diabetics\n* Unable to return at 3 month evaluation\n* Unwillingness to participate",{"count":144,"type":21},20,"The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.",[147,88,25],"Type 2 Diabetes Mellitus",[149],"Left Ventricular Assist Device (LVAD)","2026-05-05",{"date":126,"type":33},{"date":153,"type":33},"2023-11-10",{"date":155,"type":21},"2027-07",{"name":157,"class":75},"Mayo Clinic",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":51,"phases":168,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":39},"100488671","enhancing-shared-decision-making-to-guide-care-for-people-with-dementia-and-diabetes-100488671","NCT05643144","Enhancing Shared Decision-making to Guide Care for People With Dementia and Diabetes","Enhancing Shared Decision-making to Prompt and Guide Individualized Care for People With Alzheimer's Disease and Diabetes","Patient-Caregiver Dyad Inclusion Criteria (Aims 1 + 2):\n\n* patient must have dual diagnosis of MCI or ADRD and diabetes (DM)\n* patient must have active prescriptions for DM\n* patient must have had at least one visit to an Eskenazi or IU Health primary care clinic within 12 months\n* patient must be able to provide assent and have a legally authorized representative (LAR) consent on their behalf if patient lacks capacity to consent\n* patient must have a caregiver aged 18 years or older who interacts daily, or almost daily, with the patient\n* patient and caregiver must both speak English\n* patient and caregiver must both reside in the community\n* dyad must have internet access\n\nPatient-Caregiver Dyad Exclusion Criteria (Aims 1 +2):\n\n* patient has terminal illness\n* use of an automated insulin delivery system\n* patient is receiving dialysis\n* patient is taking ascorbic acid during monitoring period\n* patient has existing implanted medical devices\n* patient has a bleeding disorder\n* patient has a pre-existing arm skin lesions\n* patient has an allergy to medical adhesive or isopropyl alcohol\n* patient has plans for imaging or diathermy treatment during the study period\n\nClinician Participant Inclusion Criteria (Aim 2):\n\n* primary care physicians\n* nurses\n* pharmacists\n* nutritionists\n* psychologists\n* medical residents\n\nClinician Participant Exclusion Criteria (Aim 2):\n\n* only treats patients younger than 65 years\n* does not manage patients' DM","65 Years",{"count":167,"type":21},62,[53],"The goal of this study is to test CGM ASSIST. This is a digital tool that uses an interactive information display-an easy-to-read screen designed to help people with dementia (or memory loss) and diabetes, as well as their caregivers and doctors.\n\nManaging diabetes is often difficult for people with memory issues. This study uses a Continuous Glucose Monitor (CGM), which is a device that tracks blood sugar levels in real-time. CGM ASSIST adds a new way to see this data through interactive displays. These displays show clear information and medical guidelines to help patients and caregivers make sense of the glucose readings.\n\nThe study aims to:\n\n* Increase Awareness: Help patients and caregivers recognize the dangers of low blood sugar (hypoglycemia) and how to treat it.\n* Improve Teamwork: Encourage \"shared decision-making,\" where patients, caregivers, and doctors work together to make health choices.\n* Test Feasibility: See if it is easy and helpful for people with memory loss to use these interactive displays in their daily lives.\n* Understand Experiences: Learn how the thoughts and feelings of patients and families affect how they manage diabetes.\n\nBy using these interactive displays, the researchers hope to make it easier for families to understand their health needs and communicate better with their medical team.\n\nParticipants will:\n\n* Answer a survey about how they manage their diabetes\n* Learn how to use a Continuous Glucose Monitor and wear it for 14 days\n* Answer 3 brief telephone surveys during these 14 days\n* Complete a clinic visit with their doctor and answer a final survey on how this visit went using the CGM ASSIST report",[90,171,172,25],"Alzheimer's Disease (Incl Subtypes)","Dementia",[174,175,176,177],"Continuous glucose monitoring","Shared decision-making","Human factors","Primary care",{"date":179,"type":33},"2026-05-07",{"date":181,"type":21},"2026-07-10",{"date":183,"type":21},"2027-06-30",{"name":134,"class":75},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":192,"maxAge":165,"enrollmentInfo":193,"targetDuration":4,"studyType":51,"phases":195,"briefSummary":198,"conditions":199,"keywords":215,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":227,"locationsCount":39},"100560306","phase-1-a-study-to-investigate-safety-and-effectiveness-of-porcine-pancreatic-cells-opf-310-in-patients-with-type-1-diabetes-mellitus-100560306","NCT06575426","A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus","A Phase I\u002FIIa, Single Site, Open-Label, Ascending Dose Study to Evaluate the Safety and Efficacy of OPF-310 [Encapsulated Porcine Islet Cells for Xenotransplantation] in Subjects With Type 1 Diabetes Mellitus","Inclusion Criteria:\n\n1. Subject must be aged 35 to 65 years of age inclusive, at the time of signing the informed consent.\n2. Subject has an established diagnosis of type 1 diabetes mellitus (T1DM)(in accordance with the American Diabetes Association's criteria), with a minimum duration since diagnosis of 5 years.\n3. If one of the following criteria (either a or b) applies:\n\n   1. Subject has unstable T1DM, not achieving adequate control after receiving CLS (CGM:Dexcom G6, insulin pump: Omnipod® 5 or t:slim X2) under care of a qualified diabetes team for at least 6 months prior to enrollment.\n   2. Subject has unstable T1DM, not achieving adequate control after receiving CLS (CGM:Dexcom G7, insulin pump: Omnipod® 5, t:slim X2, iLet Bionic Pancreas or The Tandem Mobi System) under care of a qualified diabetes team for at least 6 months prior to enrollment.\n4. If one of the following criteria (either a, b or c) applies:\n\n   1. Subject has had a Level 3 (severe) hypoglycemic episode (defined as having cognitive impairment requiring external assistance for recovery) at least three times within the 1 year prior to enrollment recorded in the medical record or patient log.\n   2. Subject has had a Level 3 (severe) hypoglycemic episode at least once within the 1 year prior to enrollment and demonstrates a Clarke Score ≥4, assessed by trained study personnel. The SHE(s) and Clarke Score must be recorded in the medical record or patient log.\n   3. Subject has had TBR \\>1% at glucose levels below 70mg\u002FdL and demonstrates a Clarke Score≥4, assessed by trained study personnel. TBR data used for screening and Clarke score must be recorded in the medical record or patient log.\n5. Subject has C-peptide \\\u003C0.3 ng\u002FmL following a mixed meal tolerance test or undetectable fasting C-peptide.\n6. Hemoglobin A1C (HbA1c) ≤ 9.0\n7. Contraceptive use must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies\n8. Subject who can agree to cooperate with lifetime follow-up after transplantation.\n9. Subject is capable of providing signed informed consent\n\nExclusion Criteria:\n\n1. Previous history of insulin resistance (defined as an average insulin dose requirement ≥ 0.8 unit\u002Fkg\u002Fday for 1 week prior to enrollment).\n2. Subject has latent autoimmune diabetes in adults (LADA), ketosis-prone (Flatbush) diabetes, or maturity onset diabetes of the young (MODY).\n3. CRP ≥ 10 mg\u002FL.\n4. Clinically unstable thyroid disease (thyroid stimulating hormone (TSH)\\\u003C the lower limit of the normal range of TSH at the site.) Patients with subclinical hyperthyroidism can be rescreened once TSH levels normalize due to treatment or other factors. In addition, patients with transiently abnormal TSH levels may undergo rescreening only once during the screening period.\n5. History of malignancies within the past 5 years, excluding basal and squamous cell carcinoma\n6. Positive serologies or nucleic acid testing for human immunodeficiency virus (HIV), hepatitis C, and hepatitis B.\n7. Active or untreated proliferative diabetic retinopathy. Subjects may be rescreened once they are successfully treated.\n8. Serious comorbid conditions that are likely to affect participation in the study, including:\n\n   1. Within the last 12 months, peripheral vascular disease with previous amputation.\n   2. History of New York Heart Association (NYHA) class II, III or IV congestive heart failure (CHF) and\u002For chronic atrial fibrillation.\n   3. Chronic obstructive pulmonary disease (COPD) or asthma with previous hospitalization for decompensation; a requirement for mechanical ventilation at any stage; or long- term treatment with oral corticosteroids.\n   4. Macroalbuminuria (\\> 300 mg albumin\u002Fgm creatinine).\n   5. Estimated glomerular filtration rate (eGFR) cut-off of \\\u003C 30 ml\u002Fmin for all per Kidney Disease Improving Global Outcomes (KDOQI) and Kidney Disease Outcomes Quality Initiative (KDIGO) consensus.\n9. Use of warfarin or other anticoagulant therapy (except aspirin), or prothrombin time and international normalized ratio (PT-INR) \\> 1.5\n10. Adrenal insufficiency being treated with corticosteroids\n11. Previous pan-peritonitis\n12. Previous cardiovascular or cerebrovascular disease. NOTE: For the purposes of this exclusion criterion, \"previous cardiovascular disease\" is defined as the presence of co-existing cardiac disease, characterized by any of the following conditions:\n\n    1. Recent myocardial infarction (within past one year), or\n    2. Angiographic evidence of non-correctable coronary artery disease, or\n    3. Evidence of ischemia on functional cardiac exam (with a stress echo test recommended for subjects with a history of ischemic disease), or\n    4. Heart failure \\> NYHAII\n13. Patients with hematopoietic stem cell abnormalities (e.g., aplastic anemia, myelodysplastic syndrome)\n14. Patients who received a blood transfusion in the previous 90 days, are anticipated to undergo surgery during the 1-year study period that may require transfusion, or have donated blood within the previous 90 days.\n15. Previous receipt of an organ, skin allograft, or other tissue transplant from an allogeneic human or animal donor.\n16. Treatment with immunosuppressive medication.\n17. Previous abdominal surgery, excluding uncomplicated appendectomy, cholecystectomy, exploratory laparoscopy and hernia repair performed prior to 12 weeks prior to enrollment.\n18. Treatment with any hypoglycemic medication prescribed for glycemic control, other than insulin therapy.\n19. Treatment with acetaminophen or hydroxycarbamide.\n20. Use of any investigational products within 12 weeks of enrollment (before entering run-in) or 5 half-lives of the investigational product, whichever is greater.\n21. Subject has history of allergy to antibiotics (Amphotericin B, Cefazolin, Ciprofloxacin, Gentamicin), which are used during manufacture of OPF-310.\n22. Previous history of insulin allergy (including porcine insulin), pork product allergy or alginate\u002Fseaweed allergy.\n23. Panel reactive antibodies (PRA) \\> 80 %.\n24. Active drug, substance or alcohol addiction.\n25. Body mass index (BMI) \\>27 kg\u002Fm2.\n26. Any other condition that, in the opinion of the Investigator, may interfere with adherence to the study protocol, including dementia, psychiatric disorder, medical condition, or a history of non-adherence to appointments or treatments","35 Years",{"count":194,"type":21},13,[196,197],"PHASE1","PHASE2","This study is First In Human study for Encapsulated Porcine Islet Cells for Xenotransplantation (OPF-310). The purpose of this study to assess the safety, tolerability, and efficacy of OPF-310 transplantation and to define the recommended Phase 2 dose (RP2D) in adult subjects with unstable Type 1 Diabetes Mellitus (T1DM) and a level 3 (severe) hypoglycemic episode at least three times within the 1 year prior to enrollment despite treatment with a closed loop system (CLS) for at least 6 months.",[200,25,201,56,202,203,204,205,206,207,208,209,210,211,212,213,214],"Diabetes Mellitus, Type 1","Islet Cell Transplantation","Type 1 Diabetes Mellitus","T1D","T1DM","T1DM - Type 1 Diabetes Mellitus","Type 1 Diabetes (T1D)","Severe Hypoglycemia","Xenotransplantation","Hypoglycemic Episode","Islet Transplantation in Diabetes Mellitus Type 1","Glucose Metabolism Disorders (Including Diabetes Mellitus)","Immune System Diseases","Autoimmune Diseases","Metabolic Disease",[216,217,204,25,218,219,208,220,202,56],"Diabetes Mellitus","Diabetes Mellitus, Type1","islet cell transplantation","pig islet cell transplantation","Porcine islet cell transplantation","2026-02-26",{"date":223,"type":33},"2026-03-02",{"date":225,"type":33},"2025-06-10",{"date":183,"type":21},{"name":228,"class":229},"Otsuka Pharmaceutical Factory, Inc.","INDUSTRY",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":237,"targetDuration":239,"studyType":22,"phases":4,"briefSummary":240,"conditions":241,"keywords":244,"overallStatus":247,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":4},"100618312","fear-of-hypoglycemia-in-patients-with-diabetes-100618312","NCT07329985","FEAR of HYPOGLYCEMIA in PATIENTS WITH DIABETES","THE EFFECT OF FEAR OF HYPOGLYCEMIA ON DIET AND MEDICATION ADHERENCE IN PATIENTS WITH DIABETES","Inclusion Criteria:\n\nDiagnosed with diabetes Aged 18-65 Having experienced at least one hypoglycemic attack previously, Using antidiabetic medication (oral pills and\u002For insulin), Volunteered to participate in the study\n\nExclusion Criteria:\n\nunable to communicate in the same language having cognitive impairment wanting to leave the study at any stage",{"count":238,"type":21},100,"1 Day","Fear of hypoglycemia has a significant impact on both medication and dietary adherence in individuals with diabetes. Through avoidance behaviors, it can disrupt metabolic control, prevent the achievement of glycemic targets, and increase the risk of long-term complications. Therefore, monitoring only biochemical parameters is insufficient in diabetes management. It is crucial for healthcare professionals to systematically assess the fear of hypoglycemia.",[216,242,243,25],"Diet, Healthy","Medication Adherence",[90,243,245,246],"Nursing","Diet","NOT_YET_RECRUITING","2026-02-19",{"date":250,"type":33},"2026-02-20",{"date":252,"type":21},"2026-04-15",{"date":254,"type":21},"2026-12-15",{"name":256,"class":75},"Bilecik Seyh Edebali Universitesi",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":264,"sex":16,"minAge":17,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":51,"phases":268,"briefSummary":270,"conditions":271,"keywords":272,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":39},"100552223","early-phase-1-effect-of-c-peptide-on-hypoglycemic-counterregulation-100552223","NCT06470295","Effect of C-peptide on Hypoglycemic Counterregulation","On the Regulation of Hepatic Glucose Metabolism During Insulin-induced Hypoglycemia","Inclusion Criteria:\n\n* BMI less than 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* pregnant or lactating women cigarette smoking presence of HIV or hepatitis presence of cardiovascular disease presence of microvascular disease",true,"40 Years",{"count":267,"type":21},38,[269],"EARLY_PHASE1","Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose production and increases the depth and duration of hypoglycemic episodes. We have observed that the naturally occurring protein C-peptide increases glucagon secretion in dogs during insulin-induced hypoglycemia, which increases hepatic glucose production; the experiments in this application will shed light on the translation of this finding to the human.",[25,56],[273,274,275],"glucagon","hepatic glucose production","C-peptide","2026-02-13",{"date":278,"type":33},"2026-02-17",{"date":280,"type":33},"2024-06-01",{"date":282,"type":21},"2028-01-01",{"name":284,"class":75},"University of Cincinnati",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":294,"conditions":295,"keywords":297,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":39},"100614969","sexual-activity-and-hypoglycemia-risk-in-adults-with-type-1-or-type-2-diabetes-using-insulin-therapy-and-continuous-glucose-monitoring-100614969","NCT07286500","\"Sexual Activity and Hypoglycemia Risk in Adults With Type 1 or Type 2 Diabetes Using Insulin Therapy and Continuous Glucose Monitoring\"","\"Impact of Sexual Activity on Hypoglycemia Risk in Adults With Type 1 and Type 2 Diabetes Under Insulin Therapy and Continuous Glucose Monitoring (CGM)\"","SEX-HYPO-CGM","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Diagnosis of type 1 or type 2 diabetes.\n* Current use of a continuous glucose monitoring (CGM) system.\n* Treatment with insulin therapy in any regimen.\n* Ability to operate the CGM application and mark the start of sexual activity.\n* Willingness to participate for 3 months.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Inability to independently use the CGM application.\n* No sexual activity during the study period.\n* Withdrawal of consent at any time.\n* Any condition that, in the opinion of the investigator, prevents safe participation.",{"count":238,"type":21},"This observational study examines whether sexual activity influences the risk of hypoglycemia in adults with type 1 or type 2 diabetes treated with insulin therapy and using continuous glucose monitoring (CGM). Many patients report fear of hypoglycemia during or after sexual activity, which may affect their quality of life and willingness to engage in intimate relationships. However, no systematic research has been conducted on this topic, largely due to the sensitive nature of sexual health and the previous lack of tools to remotely monitor glucose profiles.\n\nThe study uses CGM systems (LibreView or Dexcom Clarity) to evaluate glucose changes during and up to 6 hours after sexual activity. Participants will mark the start of sexual activity in their CGM application using a neutral symbol (such as a heart icon). Data will be collected remotely through secure, certified platforms without the need for discussing details of intimate life. Glucose profiles from days with and without sexual activity will be compared. Each participant will be observed for 3 months.\n\nThe study will include 100 adults with type 1 or type 2 diabetes who use CGM and insulin therapy. By analyzing episodes of glucose levels below 70 mg\u002FdL during or after sexual activity, the study aims to determine whether sexual activity is associated with an increased risk of hypoglycemia. Findings may help to better understand patient concerns, reduce unnecessary fear, and develop future clinical recommendations for safe sexual activity in individuals treated with insulin.",[206,296,25],"Type 2 Diabetes (T2DM)",[298,25,299,300,301,302,56,303,304],"Sexual Activity","Glucose Variability","Continuous Glucose Monitoring","CGM","Insulin Therapy","Type 2 Diabetes","Diabetes Complications","2025-12-02",{"date":307,"type":33},"2025-12-16",{"date":309,"type":33},"2025-07-30",{"date":311,"type":21},"2028-07-10",{"name":313,"class":75},"Medical University of Warsaw",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":264,"sex":16,"minAge":17,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":39},"100599283","external-carotid-blood-flow-in-individuals-with-post-bariatric-hypoglycemia-100599283","NCT07082478","External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia","External Carotid Blood Flow Dynamics in Individuals With Post-Bariatric Hypoglycemia (PBH): Pilot Study","Inclusion Criteria:\n\n* Age 18-70 years of age, inclusive at screening.\n* Individuals able to provide informed consent and follow all study procedures, including complete daily food, activity, and symptom diaries, and willingness to provide access to medical record review.\n* For healthy control group: individuals without a history of upper gastrointestinal surgery and without reported symptoms of hypoglycemia.\n* Individuals with access to personal iPhone running operating system 16 (iOS) or later versions (not feasible for Android platform users) and a password-protected home Wi-Fi network.\n\nExclusion Criteria:\n\n* History of coronary artery disease or presence of 2 or more risk factors including diabetes, uncontrolled hypertension, uncontrolled hyperlipidemia, and active tobacco use.\n* History of myocardial infarction, unstable angina or revascularization within the past 6 months.\n* History of syncope (unrelated to hypoglycemia) or diagnosed cardiac arrhythmia.\n* Documented hypoglycemia occurring in the fasting state (\\> 12 hours fast).\n* Concurrent administration of β-blocker therapy.\n* Vigorous physical activity within 24 hours prior to assessment.\n* Seizure disorder (other than with suspect or documented hypoglycemia).\n* Hematocrit \\\u003C 33% (women) or \\\u003C36% (men) within the past 6 months.\n* History of insulinoma.\n* Use of central nervous system-active medications, including: antidepressants, anxiolytics, antipsychotics, stimulants, antiepileptics, sedatives and opioids.\n* History of severe neurologic vascular disease (e.g. cerebrovascular disease\u002Fstroke).\n* History of previous diseases associated with dysautonomia (e.g. multiple system atrophy, multiple sclerosis, Parkinson's disease).\n* Impaired hepatic function (aspartate amino transaminase and\u002For alanine amino transaminase \\>2x upper limit of normal range), as determined within the past 6 months.\n* Impaired renal function (serum creatinine \\>1.5 mg\u002FdL), as determined within the past 6 months.\n* Serious psychiatric or substance abuse disorders (e.g. alcohol, opioid, cocaine use disorder), as judged by the study investigator.\n* Non-consent or inability to comply with study procedures.\n* Current pregnancy and\u002F or lactation.\n* Vulnerable individuals (e.g., fetuses, children, prisoners) and those judged by the investigator to be unsuitable for the study.\n* Individuals wearing earrings or other jewelry in the left ear who are unable or unwilling to remove them for the duration of the study.\n* Unwillingness to wear study masked CGM for duration of study","70 Years",{"count":323,"type":21},5,"This is a pilot study (small-scale study) that aims to understand more about how blood flow changes in people who have low blood sugar after bariatric surgery (post-bariatric hypoglycemia) compared to those who have had surgery without hypoglycemia, those who have hypoglycemia without surgery, or those who do not experience low blood sugar.\n\nThis study has two phases. This is the first phase, and the purpose is to test comfort and feasibility of a novel in-ear wearable device (Lumia Health) that measures blood flow changes to the head. Information from the study will help the investigators determine if the device is suitable to be used in the second phase of the study.",[25,326],"Cerebral Blood Flow",[63,328,329,330,331],"postprandial hypoglycemia","bariatric surgery","autonomic dysfunction","cerebral blood flow","2025-11-26",{"date":334,"type":33},"2025-11-28",{"date":336,"type":33},"2025-07-28",{"date":338,"type":21},"2026-09-15",{"name":340,"class":75},"Joslin Diabetes Center",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":264,"sex":16,"minAge":17,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":51,"phases":351,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":106},"100243319","early-phase-1-differing-levels-of-hypoglycemia-100243319","NCT02445781","Differing Levels of Hypoglycemia","Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Differing Levels of Hypoglycemia","Inclusion Criteria:\n\n• Body mass index \\>21kg · m-2\n\nExclusion Criteria:\n\n* Pregnant women\n* Subjects unwilling or unable to comply with approved contraception measures\n* Subjects unable to give voluntary informed consent\n* Subjects on anticoagulant drugs, anemic or with known bleeding diatheses\n* Subjects with a history of severe, uncontrolled hypertension, heart disease, cerebrovascular incidents\n* Current tobacco use\n* Subjects with any known allergies to any of the study medications being used\n\nPhysical Exam Exclusion Criteria\n\n* Uncontrolled severe hypertension (i.e., blood pressure greater than 160\u002F100)\n* Clinically significant cardiac abnormalities (e.g. heart failure, arrhythmia)\n* Pneumonia treatment or hospitalization within 2 weeks prior to enrollment (study visit)\n* Hepatic failure \u002F jaundice\n* Renal failure\n* Cerebrovascular accident occurrence or hospitalization within 4 weeks prior to enrollment\n* Fever greater than 38.0 degrees C\n\nScreening Laboratory Tests Exclusion Criteria\n\n* Hematocrit lower than 32 %\n* White blood cell (WBC) count lower than 3 thou\u002Ful or greater than 14 thou\u002Ful\n* Liver function tests: serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) greater than twice upper limit of normal range\n* Alkaline phosphatase greater than 150U\u002FL\n* Total bilirubin (TBil) greater than 2 mg\u002Fdl\n* Estimated glomerular filtration rate (eGFR) less than 60 mL\u002Fmin\u002F1.73 m2\n* Positive human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C\n* Any abnormal cardiac response during multi-stage exercise test (if over 40 years of age)","55 Years",{"count":350,"type":21},32,[269],"Hypoglycemia can produce a spectrum of pro-inflammatory and pro-atherothrombotic changes. To date no studies appear to have investigated the effects of differing levels of hypoglycemia on the vasculature and pro-atherothrombotic balance during hypoglycemia in healthy man. The specific aim of our study will be to determine the effects of differing levels of hypoglycemia on in-vivo vascular biologic mechanisms in a healthy population.",[25],"2025-11-05",{"date":356,"type":33},"2025-11-10",{"date":358,"type":4},"2015-07",{"date":360,"type":21},"2026-12",{"name":362,"class":75},"University of Maryland, Baltimore",{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":51,"phases":372,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":106},"100488502","endoscopic-ultrasound-guided-large-diameter-lumen-apposing-metal-stent-gastro-gastrostomy-for-bypass-reversal-in-patients-with-roux-en-y-gastric-bypass-100488502","NCT05640947","Endoscopic Ultrasound-guided Large Diameter Lumen-apposing Metal Stent Gastro-gastrostomy for Bypass Reversal in Patients With Roux-en-y Gastric Bypass","Endoscopic Ultrasound-guided Large Diameter Lumen-apposing Metal Stent Gastro-gastrostomy for Bypass Reversal in Patients With Roux-en-y Gastric Bypass: a Proof of Concent Study","LABOR","Inclusion Criteria:\n\n* Group 1) patients needing any kind of parenteral nutritional support (eg. hypo- albuminemia, hypovitaminoses, mineral deficiencies,...) that can not be corrected by dietary intervention\u002Foral supplementation\n* Group 2) patients with persistent invalidating symptomatic dumping syndrome despite optimal dietary intervention (typical complaints are headache, sweating, trembling, weakness and feeling hungry).\n* Group 3) patients with a refractory marginal ulcers with stenosis of the gastrojejunostomy leading to feading difficulties.\n* Group 4) patients with F3 or F4 liver fibrosis and a tendency to decompensation after bypass surgery, as demonstrated by an increase in serum bilirubin\u002FINR and\u002For lowering of serum albumin.\n\nExclusion Criteria:\n\n1. Uncorrectable coagulopathy\n2. Presence of significant portal hypertension as demonstrated by 2.1) the presence of esophageal and\u002For gastric varices AND\u002FOR 2.2) a hepatic venous pressure gradient (if measured) equal to or more than 10mm Hg AND\u002FOR 2.3) the combination of\n\n   1. a platelet count \\\u003C150000\u002Fµl AND\n   2. liver stiffness measured by elastometry equal to or more than 20 kPa (Baveno guidelines).\n3. Pregnant women, breastfeeding women or women that can not assure adequate anticonception for the duration of the study (based on anamnesis).\n4. Karnofsky index less than 60\n5. Vulnerable patients",{"count":144,"type":21},[53],"The primary objective of this open-label pilot study is to investigate whether an endoscopically placed lumen apposing metal stent is an effective alternative to surgery in patients that have a clear indication for reversal of their gastric bypass.",[25,375,376,377,378],"Gastric Outlet Obstruction","Steatohepatitis","Parenteral Support","Gastric Bypass","2025-10-03",{"date":381,"type":33},"2025-10-08",{"date":383,"type":33},"2023-01-30",{"date":385,"type":21},"2028-02",{"name":387,"class":75},"University Hospital, Ghent",{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":264,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":395,"targetDuration":4,"studyType":51,"phases":397,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":106},"100132418","early-phase-1-role-of-neural-and-hormonal-regulation-factors-on-insulin-secretion-after-gastric-bypass-surgery-100132418","NCT00992901","Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery","Hormonal and Neural Control of Insulin Secretion Following Gastric Bypass Surgery","Inclusion Criteria:\n\n* Hypoglycemic RYGB patients with documented blood glucose level \\\u003C50 mg\u002Fdl\n* Asymptomatic individuals with bariatric surgery\n* Healthy non-surgical patients with no personal history of diabetes\n* Subjects must physically be able to come to our clinical research center at Cedars-Sinai Medical Center\n\nExclusion Criteria:\n\n* Active heart, lung, liver, gastrointestinal or kidney disease; unable to give informed consent; pregnancy; uncontrolled high blood pressure or high cholesterol; significant anemia (hemoglobin \\\u003C11g\u002FdL); prisoners or institutionalized individuals; type 2 diabetes melitis; development of any serious medical or psychiatric illness during recruitment or studies;\n* RYGB patients will also be disqualified if they have gastric outlet obstruction or severe diarrhea\n* Healthy non-surgical patients with personal history of diabetes\n\nFor administration of atropine, the following exclusions also apply:\n\n* History of glaucoma\n* Uncontrolled hypertension (any subjects with BP\\>140\u002F90 and history of dyslipidemia\n* Taking any medication that might interact with atropine and cannot be stopped will be excluded from the study)\n* Myasthenia gravis\n* Brain pathology\n* Enlarged prostate in men",{"count":396,"type":21},160,[269],"RYGB (roux-en-y gastric bypass) has been reported to reverse type 2 diabetes (T2DM) immediately after surgery before any significant weight loss. In addition, a growing number of patients have been recognized with life-threatening hyperinsulinemic hypoglycemia several years following their surgery. While the mechanisms by which RYGB improves glucose metabolism or alters islet cell function in patients after RYGB are not understood, recent studies suggest that increased secretion of GI hormones, primarily glucagon-like peptide 1 (GLP-1), as well as alteration in neural activity may contribute to enhanced insulin secretion in general, and to a greater extent in patients with hypoglycemia. The proposed research is designed to address the role of RYGB on insulin secretion by evaluating the contribution of stimulatory factors (neural and GI hormone) on islet cell function and the islet cell responsiveness to the physiologic stimulatory factors, in RYGB patients with and without hypoglycemia and non-operated controls.",[400,25],"Post Bariatricsurgery",[402,403,404,405],"gastric bypass surgery","glucose tolerance","Insulin response to meal ingestion","Gut hormone and neural response to meal ingestion","2025-09-08",{"date":408,"type":33},"2025-09-09",{"date":410,"type":4},"2009-10",{"date":412,"type":21},"2027-08",{"name":414,"class":75},"The University of Texas Health Science Center at San Antonio",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":264,"sex":16,"minAge":17,"maxAge":265,"enrollmentInfo":423,"targetDuration":4,"studyType":51,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":39},"100378443","evaluating-glial-acetate-metabolism-as-a-biomarker-of-hypoglycemic-counterregulation-100378443","NCT04207619","Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation","Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation Using 13C Magnetic Resonance Spectroscopy.","E-VAL","Inclusion Criteria:\n\n* Healthy male or female\n* Ages 18-40 years\n* BMI between 20 kg\u002Fm2 and 30 kg\u002Fm2 (±0.5 kg\u002Fm2 will be accepted)\n* Medically cleared for participation in the study\n\nExclusion Criteria:\n\n* Contraindication to MRI\n* Consume \\>10 alcoholic drinks\u002Fweek\n* History of chronic smoking or have quit less than 10 years ago\n* History of clinically diagnosed diabetes or a fasting blood glucose \\>126 mg\u002FdL\n* Average screening blood pressure \\>140\u002F90 mmHg\n* History of cardiovascular disease\n* Pregnant, planning to become pregnant, or breastfeeding\n* Use of medications affecting glucose metabolism, e.g., benzodiazepines, thiazide diuretics, cortisone, and prednisone.\n* Use of beta-adrenergic antagonists.\n* Based on the investigative team's clinical judgement, a subject may not be appropriate for participation in the study.",{"count":424,"type":21},10,[53],"Hypoglycemic complications are a major impediment to the maintenance of healthy glucose levels in persons with diabetes. The investigators recently completed a clinical pilot and feasibility study (GLIMPSE, NCT02690168), which identified a novel biomarker, glial acetate metabolism, that appears to predict the susceptibility to hypoglycemia. By providing an assay to predict hypoglycemic events and therefore diabetic complications, the development of this biomarker could significantly improve the treatment of persons with diabetes.\n\nThe goal of this study is to determine the efficacy of our biomarker for predicting susceptibility to insulin-induced hypoglycemia. In order to accomplish this goal the investigatiors will pair our 13C magnetic resonance spectroscopy procedure to assess glial acetate metabolism, developed in the GLIMPSE study, with a hyperinsulinemic-hypoglycemic clamp procedure, developed in the HYPOCLAMP study (NCT03839511). The two procedures will be separated by a three day interval. The investigators will then correlate the participants' rates of glial acetate metabolism with their neuroendocrine responses to the hypoglycemic clamp. This proof of concept study will test the hypothesis that glial acetate metabolism is inversely proportional to the neuroendocrine response to hypoglycemia, that is, as glial acetate metabolism increases the neuroendocrine response will decrease.",[90,25],"2025-07-21",{"date":430,"type":33},"2025-07-24",{"date":432,"type":33},"2020-02-19",{"date":434,"type":21},"2026-09",{"name":436,"class":75},"Pennington Biomedical Research Center",{"id":438,"slug":439,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":11,"sex":16,"minAge":445,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":51,"phases":448,"briefSummary":449,"conditions":450,"keywords":452,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":464},"100538872","safer-aging-with-diabetes-monitoring-100538872","NCT06296485","Safer Aging With Diabetes Monitoring","Pragmatic Clinical Trial of Continuous Glucose Monitoring-based Interventions for Safe Insulin Use in High-Risk Older Adults With Type 2 Diabetes","SAGE","Inclusion Criteria:\n\n* Age 75 years and older\n* Diagnosis of Type 2 Diabetes\n* Current treatment with insulin\n* Increased hypoglycemia risk (prior year hypoglycemia by self-report or utilization)\n* Able to communicate in English\n* Able to access email and the Internet\n\nExclusion Criteria:\n\n* On renal dialysis\n* Dementia\n* Pacemaker or Automatic Implantable Cardioverter Defibrillator\n* Using insulin pump\n* Severe Mental Illness\n* Severe Visual Impairment\n* In Hospice\n* Current or recent CGM use","75 Years",{"count":447,"type":21},360,[53],"Older adults with type 2 diabetes are at higher risk for severe hypoglycemia and its related complications (including hospitalization and death) when taking insulin. This study proposes to evaluate, in a randomized clinical trial, a strategy of safe insulin prescribing based on an educational program that leverages continuous glucose monitoring to support older adults at high risk for hypoglycemia. If the aims of this project are achieved, this novel care strategy could be widely applied to reduce severe hypoglycemia episodes in older, high-risk adults with type 2 diabetes.",[451,25],"Diabetes Mellitus, Type 2",[25,453,454],"Diabetes Education","Continuous Glucose Monitor","2025-04-21",{"date":457,"type":33},"2025-04-22",{"date":459,"type":33},"2024-05-01",{"date":461,"type":21},"2028-01-31",{"name":463,"class":75},"Kaiser Permanente",4,{"id":466,"slug":467,"hasResults":11,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":39},"100377276","digestnewborn-study-100377276","NCT04192422","DiGESTnewborn Study","Glucose Control and Metabolic Adaptation in Offspring of Women With Gestational Diabetes Recruited to the DiGest Study","DiGESTnewborn","Inclusion Criteria:\n\n* mothers and their babies who have been enrolled in DiGest Trial and who have provided informed consent\n\nExclusion Criteria:\n\n* none",{"count":474,"type":21},60,"We wish to study the effect of a mothers sugar (glucose) control during pregnancy on her baby's sugar control after birth.",[477,25],"GDM","2025-04-15",{"date":480,"type":33},"2025-04-17",{"date":482,"type":33},"2020-09-01",{"date":484,"type":21},"2026-12-31",{"name":486,"class":75},"Cambridge University Hospitals NHS Foundation Trust",{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":493,"targetDuration":4,"studyType":51,"phases":494,"briefSummary":495,"conditions":496,"keywords":498,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":39},"100514078","effect-of-fasting-on-hypoglycemic-counterregulation-in-type-1-diabetes-100514078","NCT05973799","Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes","Inclusion Criteria:\n\n* males and females of any race or ethnicity\n* non-obese (BMI \\\u003C or = to 30)\n* have a diagnosis of type 1 diabetes\n* C-peptide negative\n\nExclusion Criteria:\n\n* pregnant women\n* cigarette smoking\n* Taking inflammation-targeting steroids (e.g., prednisone).\n* Taking medications targeting adrenergic signaling (e.g., beta-blockers, bronchodilators).\n* Hematocrit less than 33%.\n* Presence of HIV or hepatitis (due to their deleterious effects on the liver).\n* The presence of cardiovascular or peripheral vascular disease.\n* The presence of neuropathy, retinopathy or nephropathy.\n* A detection of the presence of any other disease or condition by one of the study doctors, that would be expected to confound the responses to insulin-induced hypoglycemia or make participation in the study dangerous to the individual.",{"count":424,"type":21},[53],"Iatrogenic hypoglycemia is still considered to be the number one barrier to effective glycemic control in patients with type 1 diabetes (T1D). In a previous study, it was observed in people without diabetes that fasting can be detrimental to the hormonal and hepatic responses to insulin-induced hypoglycemia. In the experiments described herein, the impact fasting has on hypoglycemic counterregulation in people with T1D will be determined.",[25,497],"Type1diabetes",[273,499,500],"hepatic glucose metabolism","liver glycogen","2024-08-29",{"date":503,"type":33},"2024-09-03",{"date":505,"type":33},"2019-10-10",{"date":507,"type":21},"2024-12-31",{"name":284,"class":75},{"id":510,"slug":511,"hasResults":11,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":516,"enrollmentInfo":517,"targetDuration":4,"studyType":51,"phases":519,"briefSummary":520,"conditions":521,"keywords":523,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":532,"locationsCount":534},"100559404","continuous-glucose-monitoring-in-hie-100559404","NCT06563687","Continuous Glucose Monitoring in HIE","Real-time Continuous Glucose Monitoring in Infants With Hypoxic-ischaemic Encephalopathy: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Birth weight \\>1.8kg\n* Gestation \\>35 weeks\n* Aged \\\u003C6hours\n* Moderate or severe HIE following perinatal asphyxia\n\nExclusion Criteria:\n\n* Major congenital malformations\n* Inborn errors of metabolism,\n* Congenital infections\n* Imminent death","6 Hours",{"count":518,"type":21},70,[53],"The aim of the study is to examine whether the use of continuous glucose monitoring (CGM) to guide the clinical management of glycaemic control will result into an increased time in the target glucose concentration. To further examine the efficacy of using CGM the following secondary outcomes in the two groups were assessed: mean glucose values, glucose variability within individuals, percentage of time that glucose values are in hyperglycaemic or hypoglycaemic ranges.\n\nRandomized controlled trial recruiting neonates (Birth weight \\>1.8kg, Gestation\\>36 weeks) with moderate or severe hypoxic ischemic encephalopathy (HIE) following perinatal asphyxia . Neonates will be randomly assigned (1:1) within 6 hours of birth to receive either the intervention with real-time CGM or standard care for 72 hours.",[522,88,25],"Hypoxic Ischemic Encephalopathy of Newborn",[174,524,525],"Neonatal hypoglycemia","Neonatal hyperglycemia","2024-08-20",{"date":528,"type":33},"2024-08-21",{"date":530,"type":33},"2024-08-01",{"date":132,"type":21},{"name":533,"class":75},"University of Campania Luigi Vanvitelli",3,{"id":536,"slug":537,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":544,"conditions":545,"keywords":548,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":39},"100534127","continuous-subcutaneous-glucose-monitoring-in-critical-patients-100534127","NCT06234787","Continuous Subcutaneous Glucose Monitoring in Critical Patients","Continuous Subcutaneous Glucose Monitoring: A Descriptive Study of Its Use in Critical Patients","Inclusion Criteria:\n\n* The study will be conducted in patients admitted to the ICU of HLA Moncloa Hospital over four years. Patients admitted to the ICU, undergoing insulin treatment, and having a CGM sensor.\n* Patients who sign the voluntary consent to participate in the study (Annex 2). If the participant is not in full physical or intellectual capacity to provide their signature on the informed consent, the responsible investigator will request such consent from their direct family member or the person legally designated to make decisions on their behalf regarding health matters. This measure is taken to ensure that the participant\\'s rights are respected, and the integrity of the consent process is maintained, even in situations where their decision-making capacity may be compromised.\n\nExclusion Criteria:\n\n* Patients from whom information on CGM cannot be obtained for technical reasons.",{"count":543,"type":21},245,"This is a single-center, observational, descriptive, longitudinal, and prospective study This study aims to determine the cumulative incidence during admission and the incidence rate of potential hypoglycemic events (defined as subcutaneous glucose \\\u003C80 mg\u002FdL detected by CGM) in patients admitted to the Intensive Care Unit (ICU) of HLA Moncloa Hospital over four years of follow-up. The study also aims to document the occurrences of hypoglycemic events, describe the characteristics of patients receiving CGM sensors, and outline the actions taken as a result of detecting potential hypoglycemic events",[88,25,90,546,547],"Critical Care","Critically Ill Patients",[549,550,551,63],"continuous subcutaneous glucose monitoring","critical care","intensive care","2024-02-01",{"date":554,"type":33},"2024-02-05",{"date":556,"type":33},"2023-11-30",{"date":558,"type":21},"2027-12-01",{"name":560,"class":75},"Universidad Europea de Madrid",{"id":562,"slug":563,"hasResults":11,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":11,"sex":16,"minAge":569,"maxAge":570,"enrollmentInfo":571,"targetDuration":573,"studyType":22,"phases":4,"briefSummary":574,"conditions":575,"keywords":578,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":39},"100412993","french-national-cohort-of-people-with-type-1-diabetes-100412993","NCT04657783","French National Cohort of People With Type 1 Diabetes","French National Cohort of People With Type 1 Diabètes: the SFDT1 Study","SFDT1","1. Inclusion Criteria\n\n   * Adults and children (age \\>= 6 years)\n   * Type 1 diabetes, defined as:\n   * Age at diagnosis of diabetes \\> 1 year and \\\u003C= 35 years\n   * Insulin treatment initiated within the first 12 months following diabetes discovery\n   * Affiliation to the French social security scheme (RIPH-2 constraint)\n   * Ability to speak and read French\n   * Ability to give written informed consent\n2. Non-inclusion Criteria Patient under guardianship or protection for vulnerable people","6 Years","100 Years",{"count":572,"type":21},15000,"10 Years","Cardiovascular (CV) diseases are the most frequent type 1 diabetes (T1D) complications. A recent epidemiological study showed that patients with T1D have a two-fold CV mortality risk, even in case of good glycemic control. In addition, it has been shown that patients with T1D with no traditional CV risk factors had about a 80% higher risk of cardiovascular event compared to non-diabetic individuals. This indicates that further modifiable risk factors in relation to CV mortality remain to be identified.\n\nOne of the candidates that could help to disentangle the factors associated with the increased CV mortality in T1D patients is glycemic variability which could contribute to diabetes complications. Indeed, severe hypoglycaemia, one of the most severe consequence of glycaemic variability, are associated with a higher mortality in patients with type 1 and type 2 diabetes.\n\nIn order to evaluate the relation between glycemic variability, insulin therapy modalities and CV risk as well as some other questions related to health determinants of T1D, we are building up a large observational, prospective, multi-centric cohort study of patients gathering 15,000 patients with T1D, age above 6 years old, to perform the following:\n\n* Collecting clinical information\n* Evaluating Glycemic variability (assessed by the coefficient of variation of glucose (CV) calculated from automatically downloaded continuous glucose monitoring data (CGM)\n* Biobanking including plasma, DNA, urine, saliva and hair.\n* Collecting patients' reported outcomes through auto-questionnaires (online questionnaires).\n* Doing an active follow-up for a period of 10 years with an intermediate visit every 3 years.\n* Passive follow-up: link to national Health data system (Système National de Données de Santé, SNDS) in order to exhaustively collect health events as death, CV events and hospitalizations (including severe hypoglycemia).",[200,576,25,577],"Cardiovascular Diseases","Patient Participation",[60,579,580,63,581,582],"cardiovascular disease","glucose variability","quality of life","insulin therapy","2023-02-13",{"date":585,"type":33},"2023-02-15",{"date":587,"type":33},"2020-06-10",{"date":589,"type":21},"2035-06-10",{"name":591,"class":75},"Fondation Francophone pour la Recherche sur le Diabete"]